Clene Inc. (CLNN)
4.59
-0.15 (-3.16%)
At close: Feb 20, 2025, 3:59 PM
4.51
-1.74%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 4.4 |
| Market Cap | 38.22M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -5.29 |
| PE Ratio (ttm) | -0.87 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.6 |
| Volume | 57,645 |
| Avg. Volume (20D) | 80,023 |
| Open | 4.61 |
| Previous Close | 4.74 |
| Day's Range | 4.42 - 4.87 |
| 52-Week Range | 3.82 - 10.40 |
| Beta | undefined |
About CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; com...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 18, 2018
Employees 82
Stock Exchange NASDAQ
Ticker Symbol CLNN
Website https://clene.com
Analyst Forecast
According to 5 analyst ratings, the average rating for CLNN stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 575.38% from the latest price.
Buy 80.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Clene Inc. is scheduled to release its earnings on Mar 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
6 months ago
-23.47%
Clene shares are trading lower after the company r...
Unlock content with
Pro Subscription
10 months ago
-6.49%
Clene shares are trading higher after the company announced Phase 2 VISIONARY-MS long term extension study results at the 2024 American Academy of Neurology Annual Meeting.
